Please assess the completion status of the following clinical trial:

Trial Title: Optimal Oral Hypoglycaemic Agents (OHA) for Combination With Insulin Glargine (Sulfonylurea vs. Metformin)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes for at least 6 months~* Treated with maximal, tolerable dose of metformin (≥ 1000mg/day) and sulfonylurea (glimepiride≥ 4 mg/day or equivalent dose of other SU) for at least 3 months prior to the screening visit~* 7.0 \< HbA1c \< 11 %~* Fasting serum C-peptide \> 0.33 nmol/L~* BMI \< 30 kg/m²~* Patients who is willing to monitor BG using SMBG~Exclusion Criteria:~* Type 1 Diabetes~* Clinical evidence of active liver disease, or serum ALT 3 times the upper limit of the normal range~* Serum creatinine: ≥ 1.5 mg/dl for males, ≥ 1.4 mg/dl for females~* Active proliferative diabetic retinopathy, as defined by the application of photocoagulation or surgery, in the 6 months before study entry or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgery during the study (an optic fundus examination should have been performed in the 2 years prior to study entry)~* History of alcohol or other substance abuse~* Pregnancy or not using contraceptive in childbearing aged women~* Breast feeding women~* History of hypersensitivity to the study drugs or to drugs with a similar chemical structure~* Treatment with any medication including corticosteroid or herbal medicines that can affect blood glucose level within 3 months prior to study entry except metformin and sulfonylurea.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Administration of 4 mg of Glimepiride with Insulin Glargine
- 2 (Type: ACTIVE_COMPARATOR): Administration of 1500 mg of Metformin with Insulin Glargine
- 3 (Type: EXPERIMENTAL): Administration of a combination of 4mg Glimepiride plus 1000mg Metformin with Insulin Glargine

Based on this trial design, predict the completion outcome and termination type (if applicable).